Physician profile
Debbie Tobin
NPI 1467662304
$3,122.69
in general payments reported to CMS, 2019-2025
30 companies · $749 in 2025
The $749 reported for 2025 was more than what 93% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $683 · 2022: $708 · 2023: $770 · 2024: $213 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.08 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.94 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $295.53 | 2021-2025 | |
| Exeltis, USA INC. | $244.39 | 2021-2025 | Slynd |
| Evofem Biosciences, INC. | $201.86 | 2021-2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $167.55 | 2021-2025 | |
| Astellas Pharma US INC | $162.05 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $158.56 | 2023-2025 | Myfembree, Gemtesa |
| Organon LLC | $126.22 | 2022-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $115.68 | 2021-2025 | |
| Daiichi Sankyo INC. | $107.52 | 2021-2022 | |
| Myovant Sciences INC. | $105.84 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $95.86 | 2023 | Myrisk |
| Millicent US INC | $93.10 | 2025 | Femlyv |
| Coopersurgical, INC. | $89.50 | 2022-2025 | Paragard T 380a, Endosee |
| Therapeuticsmd, INC. | $87.97 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $83.40 | 2025 | Zurzuvae |
| Aspira Women'S Health INC | $74.49 | 2022-2024 | Ova1 |
| Agile Therapeutics, INC. | $63.24 | 2022-2024 | Twirla |
| Exact Sciences Corporation | $58.47 | 2023-2024 | Cologuard Collection Kit |
| Avion Pharmaceuticals | $52.01 | 2022 | |
| Shield Therapeutics INC | $41.33 | 2022 | |
| Mylan Pharmaceuticals INC. | $38.54 | 2021 | |
| Hologic Sales and Service, LLC | $37.25 | 2023-2024 | Aptima |
| Merck Sharp & Dohme LLC | $27.96 | 2021 | |
| Sanofi Pasteur INC. | $24.40 | 2025 | |
| Roche Diagnostics Corporation | $22.07 | 2021 | |
| Novo Nordisk INC | $19.62 | 2025 | Wegovy |
| Becton, Dickinson and Company | $17.95 | 2023 | Bd Onclarity |
| Medicem INC. | $16.08 | 2022 | |
| Dysis Medical, INC. | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.